Othera Pharmaceuticals Revenue and Competitors

Location

N/A

Total Funding

Pharma

Industry

Estimated Revenue & Valuation

  • Othera Pharmaceuticals's estimated annual revenue is currently $6.2M per year.(i)
  • Othera Pharmaceuticals's estimated revenue per employee is $201,000

Employee Data

  • Othera Pharmaceuticals has 31 Employees.(i)
  • Othera Pharmaceuticals grew their employee count by 48% last year.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$40.6M202-2%N/AN/A
#2
$74.6M37119%N/AN/A
#3
$11.7M5814%N/AN/A
#4
$1011.8M5034-9%N/AN/A
#5
$44.4M221-2%N/AN/A
#6
$12.5M627%N/AN/A
#7
$16.5M8241%N/AN/A
#8
$18.3M916%N/AN/A
#9
$59.9M29823%N/AN/A
#10
$12.9M6410%N/AN/A
Add Company

Othera is a pharmaceutical company developing novel therapeutics for age-related diseases of the eye. Othera's lead compound, OT-551 is an eye drop in a Phase II clinical trial for the dry form of macular degeneration (AMD), and recently announced positive interim data from that trial, with full trial results due in mid-2010. The company is also developing novel treatments for glaucoma and neurodegenerative diseases.

keywords:N/A

N/A

Total Funding

31

Number of Employees

$6.2M

Revenue (est)

48%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Othera Pharmaceuticals News

2022-04-17 - AI Drug Discovery Systems Might Be Repurposed to Make Chemical Weapons, Researchers Warn

In 2020 Collaborations Pharmaceuticals, a company that specializes in looking ... including not only VX but other known chemical weapons,...

2022-04-17 - AI reduces miss rate of precancerous polyps in colorectal ...

One colonoscopy used AI; the other, a standard colonoscopy, did not. ... Cosmo Pharmaceuticals, Fujifilm, Olympus and Virgo.

2022-03-22 - Could a simple dietary supplement treat Alzheimer's?

The other, a phase 1/2 trial led by Alberta Health Service, is looking at the ... pharmaceutical industry to accelerate data science driven drug discovery.

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$7.2M3111%N/A
#2
$8M3214%N/A
#3
$15M32-9%N/A
#4
$6.6M33-44%N/A
#5
$9.2M356%N/A